ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Oncotarget 2015 Apr;6(12):10577-85

Center for Integrated Oncology Köln Bonn, Cologne, Germany.

Background: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients.

Patients And Methods: 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients.

Results: 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations.

Conclusion: ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496376PMC
http://dx.doi.org/10.18632/oncotarget.3387DOI Listing
April 2015
39 Reads

Publication Analysis

Top Keywords

patients
9
stage patients
8
response chemotherapy
8
patients ros1-rearrangement
8
prognostic impact
8
patients response
8
genetically defined
4
survival compared
4
compared genetically
4
best prognostic
4
defined subgroups
4
response crizotinib
4
patients 1035
4
patientsresults patients
4
ros1-negative patientsresults
4
subgroups ros1-negative
4
crizotinib best
4
assessed survival
4
prognostic molecular
4
markers nsclc
4

Similar Publications